# ZYNRELEF for Pain Management in Total Knee Arthroplasty

> **NCT05644496** · PHASE4 · RECRUITING · sponsor: **Baptist Health South Florida** · enrollment: 242 (estimated)

## Conditions studied

- Post Operative Pain
- Osteoarthritis, Knee

## Interventions

- **DRUG:** Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release

## Key facts

- **NCT ID:** NCT05644496
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644496, "ZYNRELEF for Pain Management in Total Knee Arthroplasty". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05644496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*